Bioman: Discrete-event Simulator to Analyze Operations for Car-T Cell Therapy Manufacturing
abstract: The success of genetically-modified T-cells in treating hematological malignancies has accelerated the research timeline for Chimeric Antigen Receptor-T (CAR-T) cell therapy. Since there are only two approved products (Kymriah and Yescarta), the process knowledge is limited. This leads to...
| Other Authors: | |
|---|---|
| Format: | Dissertation |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/2286/R.I.62671 |